Outlook Therapeutics successfully secured official U.S. Food and Drug Administration approval for its flagship ophthalmic drug LYTENAVA, establishing it as the first and only FDA-approved ophthalmic formulation of bevacizumab designed specifically for the treatment of wet age-related macular degeneration. Following years of regulatory review, appeals, and resubmissions, the regulatory milestone successfully concluded the agency's evaluation phase, clearing the way for commercialization across the United States retina care market.